ArticleBritish journal of pharmacology2001
Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats.
Article in British journal of pharmacology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 102 citations in OpenAlex.
- Urotensin II evokes potent vasoconstriction in humans in vivo.British journal of pharmacology · 2002Trial
- The value of urotensin II in patients with left-sided rheumatic valvular regurgitation.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2017Article
- The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.Frontiers in endocrinology · 2017Review
- Acute Effect of Central Administration of Urotensin II on Baroreflex and Blood Pressure in Conscious Normotensive Rabbits.Frontiers in physiology · 2017Article
- Renal Urotensin II System Plays Roles in the Regulation of Blood Pressure in Dahl Salt-Resistant Rat.International journal of hypertension · 2016Article
- Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.Journal of experimental & clinical cancer research : CR · 2014Article
- A closer look at the role of urotensin II in the metabolic syndrome.Frontiers in endocrinology · 2012Article
- Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure.Digestive diseases and sciences · 2010Article
- Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling.Naunyn-Schmiedeberg's archives of pharmacology · 2007Article
- Therapeutic potential of blockade of the urotensin II system in systemic hypertension.Current hypertension reports · 2007Review
- Urotensin-II induces ear flushing in rats.British journal of pharmacology · 2007Article
- Role of urotensin II and its receptor in health and disease.Journal of anesthesia · 2007Review
- The role of urotensin II in cardiovascular and renal physiology and diseases.British journal of pharmacology · 2006Review
- Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity.Naunyn-Schmiedeberg's archives of pharmacology · 2006Article
- Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation.British journal of pharmacology · 2006Article
- Urotensin II stimulates plasma extravasation in mice via UT receptor activation.Naunyn-Schmiedeberg's archives of pharmacology · 2004Article
- Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response.British journal of pharmacology · 2004Article
- Urotensin-II: a novel systemic hypertensive factor in the cat.Naunyn-Schmiedeberg's archives of pharmacology · 2004Article
- Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.British journal of pharmacology · 2003Article
- Is urotensin-II the new endothelin?British journal of pharmacology · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The regional haemodynamic effects of rat or human urotensin II (U-II) 3, 30, 300 and 3000 pmol kg(-1), i.v.) were assessed in separate groups of conscious, unrestrained, male, Sprague-Dawley rats (n=8 in each). Rat and human U-II had similar effects. At a dose of 3 pmol kg(-1), neither peptide had any significant action, while at a dose of 30 pmol kg(-1), there was a transient mesenteric vasodilatation (significant only for rat U-II). At doses of 300 and 3000 pmol kg(-1), there were dose-dependent tachycardias, and mesenteric and hindquarters hyperaemic vasodilatations. Thus, in conscious rats, the predominant cardiovascular action of rat and human U-II is vasodilatation. This is in contrast to recent findings with human U-II in non-human primates, but is consistent with effects on human isolated resistance vessels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.